

Overview
This e-learning module explores the latest updates on amivantamab-based therapy in epidermal growth factor receptor gene (EGFR)-mutant non–small-cell lung cancer (NSCLC). It highlights efficacy data from the MARIPOSA trial as well as practical strategies to optimise safety outcomes, drawing on insights from the SKIPPirr, COCOON and PALOMA studies. Real-world patient cases illustrate how these approaches can be effectively applied in clinical practice.
Upon completion of the educational activity, health care providers should be able to: